Or should everyone with stage-2 lung adenocarcinoma with an exon 19 epidermal growth factor receptor (EGFR) mutation receive osimertinib after definitive surgery and chemotherapy or just those relapsing? This evidence concerns the gene EGFR and lung adenocarcinoma.